|
|
|
|
|||||
|
|
|
| Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter
|
| Ticker | Owner | Relationship | Date | Transaction | Cost  |
#Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Mar 05 '25 | Option Exercise | 87.49 | 14,113 | 1,234,766 | 17,841 | Mar 07 05:40 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Mar 05 '25 | Sale | 341.32 | 14,113 | 4,817,104 | 3,728 | Mar 07 05:40 PM |
| MDGL | ROBERT WALTERMIRE | Officer | Mar 05 '25 | Proposed Sale | 341.32 | 14,113 | 4,817,104 | Mar 05 04:07 PM | |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Feb 28 '25 | Sale | 341.07 | 1,227 | 418,488 | 3,728 | Mar 04 09:24 PM |
| MDGL | ROBERT WALTERMIRE | Officer | Feb 28 '25 | Proposed Sale | 341.07 | 1,227 | 418,488 | Feb 28 04:59 PM | |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Jan 24 '25 | Sale | 335.24 | 103 | 34,530 | 4,955 | Jan 27 05:03 PM |
| MDGL | Robert E Waltermire | Officer | Jan 24 '25 | Proposed Sale | 340.14 | 103 | 35,034 | Jan 24 06:00 PM | |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Jan 17 '25 | Sale | 273.41 | 442 | 120,847 | 5,058 | Jan 17 07:08 PM |
| MDGL | Robert E Waltermire | Officer | Jan 17 '25 | Proposed Sale | 272.79 | 442 | 120,573 | Jan 17 05:30 PM | |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Jun 14 '24 | Option Exercise | 87.09 | 1,900 | 165,471 | 7,400 | Jun 18 09:39 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Jun 14 '24 | Sale | 280.00 | 1,900 | 532,000 | 5,500 | Jun 18 09:39 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Jun 12 '24 | Option Exercise | 87.92 | 2,000 | 175,840 | 7,500 | Jun 14 09:44 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Jun 12 '24 | Sale | 285.00 | 2,000 | 570,000 | 5,500 | Jun 14 09:44 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | May 21 '24 | Sale | 231.34 | 1,036 | 239,668 | 5,500 | May 23 09:36 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 14 '23 | Option Exercise | 87.92 | 2,000 | 175,840 | 7,667 | Dec 18 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 15 '23 | Option Exercise | 87.92 | 2,000 | 175,840 | 7,667 | Dec 18 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 15 '23 | Sale | 238.50 | 2,000 | 477,000 | 5,667 | Dec 18 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 14 '23 | Sale | 232.50 | 2,000 | 465,000 | 5,667 | Dec 18 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 13 '23 | Option Exercise | 87.92 | 2,500 | 219,800 | 8,167 | Dec 14 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 12 '23 | Option Exercise | 87.92 | 1,300 | 114,296 | 6,967 | Dec 14 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 12 '23 | Sale | 217.85 | 1,300 | 283,200 | 5,667 | Dec 14 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 13 '23 | Sale | 225.40 | 2,500 | 563,500 | 5,667 | Dec 14 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Feb 28 '23 | Option Exercise | 87.92 | 5,000 | 439,600 | 10,667 | Mar 02 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Mar 01 '23 | Option Exercise | 87.92 | 5,000 | 439,600 | 10,667 | Mar 02 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Mar 01 '23 | Sale | 274.42 | 5,000 | 1,372,081 | 5,667 | Mar 02 04:30 PM |
| MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Feb 28 '23 | Sale | 272.07 | 5,000 | 1,360,357 | 5,667 | Mar 02 04:30 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite